Drug Profile
DB 017
Alternative Names: DB 017; rMMP10Latest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator Digna Biotech
- Class Matrix metalloproteinases; Recombinant proteins
- Mechanism of Action Fibrinolysis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 29 Aug 2023 Discontinued - Preclinical for Stroke in Spain (unspecified route) (Digna Biotech pipeline, August 2023)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Stroke in Spain
- 20 Jan 2016 Preclinical trials in Stroke in Spain (unspecified route)